

In the specification, on page 13, lines 5 and 6, please insert --(SEQ ID NO:8)-- after "GIP (7-30)-NH₂ (ANTGIP)".

In the specification, on page 13, lines 9, 10 11, 12 and 13, please insert --(SEQ ID NO:10)-- after "GIP (10-30)-NH₂".

In the specification, on page 3, lines 12, 13, 14, 15, 16, 18, 24, 27, 29 and 32, on page 4, lines 4, 6, 7, on page 5, lines 11, 13, 16, 18, 21, 23 and 29, on page 14, lines 2, 26, 31 and 32, on page 15, lines 2, 25, 28, 29 and 31, on page 16, lines 3, 8, 23, 26 and 31, on page 17, lines 2, 4, 7, 8, 9, 13, 16, 17, 21, 23, and on page 18, lines 11, 13 and 17, please insert --(SEQ ID NO:8)-- after "ANTGIP".

OR - In the specification, on page 19, line 3, kindly substitute --described-- for "describe".

In the specification, kindly insert the paper copy of the Sequence Listing" submitted herewith on page 19, begining on line 3 as a new paragraph separate from the paragraph "Having describe our invention, we claim:", which begins on line 3.

In the Claims:

Please cancel without prejudice claims 2-7 and 17, amend claims 1, 9, 10, 12 and 13, and add new claims 18-42, as follows:

a 4 (1)(AMENDED) In claim 1, line 2, kindly please substitute --human GIP, SEQ ID NO:2, or rat GIP, SEQ ID NO: 8-- for "GIP".

a 5 (9)(AMENDED) In claim 9, line 3, kindly substitute --human GIP, SEQ ID NO:2,-- for "GIP".

a 6 (10)(AMENDED) In claim 10, line 2, kindly substitute --human GIP, SEQ ID NO:2,-- for "GIP".

a 7 (12)(AMENDED) In claim 12, line 3, kindly substitute --human GIP, SEQ ID NO:2,-- for "GIP".

a 7 (13)(AMENDED) In claim 13, line 2, kindly substitute --human GIP, SEQ ID NO:2,-- for "GIP".

(18)(NEW) An antagonist according to claim 8, wherein said antagonist comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(19)(NEW) An antagonist according to claim 8, wherein said antagonist comprises a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(20)(NEW) An antagonist according to claim 11, wherein the antagonist comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(21)(NEW) An antagonist according to claim 11, wherein the antagonist comprises a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(22)(NEW) A polypeptide having an amino acid sequence which specifically interferes with the biological activity of GIP when said polypeptide is administered in an effective amount to an animal.

(23)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of human GIP, SEQ ID NO:2, or effective alternative sequences thereto.

(24)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 24 amino acids corresponding to positions 7-30 of the sequence of human GIP, SEQ ID NO:2, or effective alternative sequences thereto.

(25)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(26)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 24 amino acids corresponding to positions 7-30 of the sequence of rat GIP, SEQ ID NO:8, or effective alternative sequences thereto.

(27)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 16-30 of the sequence of human GIP, SEQ ID NO:3, or effective alternative sequences thereto.

(28)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 15 amino acids corresponding to positions 16-30 of the sequence of human GIP, SEQ ID NO:3, or effective alternative sequences thereto.

(29)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 16-30 of the sequence of rat GIP, SEQ ID NO:9, or effective alternative sequences thereto.

(30)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 15 amino acids corresponding to positions 16-30 of the sequence of rat GIP, SEQ ID NO:9, or effective alternative sequences thereto.

(31)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 10-30 of the sequence of human GIP, SEQ ID NO:5, or effective alternative sequences thereto.

(32)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 21 amino acids corresponding to positions 10-30 of the sequence of human GIP, SEQ ID NO:5, or effective alternative sequences thereto.

(33)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at least an effective number of amino acids corresponding to those amino acids in positions 10-30 of the sequence of rat GIP, SEQ ID NO 10:, or effective alternative sequences thereto.

(34)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 21
amino acids corresponding to positions ¹⁰~~21~~-30 of the sequence of rat GIP, SEQ ID NO:10, or
effective alternative sequences thereto.

(35)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at
least an effective number of amino acids corresponding to those amino acids in positions 21-30 of
the sequence of rat GIP, SEQ ID NO:13, or effective alternative sequences thereto.

(36)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 10
amino acids corresponding to positions 21-30 of the sequence of rat GIP, SEQ ID NO:13, or
effective alternative sequences thereto.

(37)(NEW) A polypeptide according to claim 22, wherein said polypeptide comprises at
least an effective number of amino acids corresponding to those amino acids in positions 31-44 of
the sequence of rat GIP, SEQ ID NO:¹⁴~~13~~, or effective alternative sequences thereto.

(38)(NEW) A polypeptide according to claim 22, wherein the polypeptide comprises 14
amino acids corresponding to positions 31-44 of the sequence of rat GIP, SEQ ID NO:¹⁴~~13~~, or
effective alternative sequences thereto.

(39)(NEW) A polypeptide having an amino acid sequence which specifically interferes
with the biological activity of GIP when said polypeptide is administered in an effective amount to
an animal, said polypeptide comprising at least those amino acids corresponding to positions 7-9 of
GIP, SEQ ID NO 6.

(40)(NEW) A polypeptide according to claim 39, wherein the polypeptide comprises 24
amino acids corresponding to positions 7-30 of the sequence of human GIP, SEQ ID NO:2, or
effective alternative sequences thereto.